ReviewFrontiers in pharmacology2024
Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Modeling symptom-acupoint interactions via a heterogeneous graph learning framework for intelligent acupoint recommendation.Chinese medicine · 2026Article
- Self-assembled nanoparticles from Xiexin Decoction attenuate ulcerative colitis by targeting VDAC1-Mediated NLRP3 inflammasome activation.Materials today. Bio · 2026Article
- Tannins as Therapeutic Agents for Ulcerative Colitis: Mechanisms and Prospects in Regulating Gut Inflammatory-Oxidative Homeostasis.Molecules (Basel, Switzerland) · 2026Review
- Yiqi Daozhi Formula Reduces the M1 Polarization of Macrophages in Mice With Postoperative Ileus Through Mediating Glycolysis Metabolism.Immunity, inflammation and disease · 2026Article
- Evaluation of electroacupuncture acupoint selection's potential in the treatment of inflammatory bowel disease: an investigation using a mouse gut microbiome and metabolomics model.Frontiers in cellular and infection microbiology · 2026Article
- Clinical efficacy of repetitive transcranial magnetic stimulation combined with electroacupuncture at Baliao points for functional constipation: a retrospective study.Frontiers in neurology · 2026Article
- Mechanism Study of Yi-Qi-Dao-Zhi Formula in Improving Postoperative Ileus by Targeting the TLR4/NF-κB/MAPK Signaling Pathways.Journal of inflammation research · 2026Article
- Zengwei Chengqi Decoction Reduces Inflammation in Acute Intestinal Obstruction.Mediators of inflammation · 2026Article
- Latent myofascial trigger point injection improves symptoms in functional gastrointestinal disorders.World journal of gastrointestinal surgery · 2025Article
- Gastrointestinal complications in intensive care.Medical review (2021) · 2025Review
- Alchemizing earth's legacy: Bismuth-engineered humic nanoparticles for IBD theranostics through mitochondrial anti-inflammation and sustained intestinal delivery.Materials today. Bio · 2025Article
- Independent role of two novel abdominal fat indicators in chronic diarrhoea.Frontiers in medicine · 2025Article
- N4BP3 Activates TLR4-NF-κB Pathway in Inflammatory Bowel Disease by Promoting K48-Linked IκBα Ubiquitination.Journal of inflammation research · 2025Article
- Dahuang gancao dandelion decoction regulates intestinal flora and inhibits NF-κB/ARA signaling pathway to alleviate ulcerative colitis.Frontiers in immunology · 2025Article
- The emerging role of honeysuckle flower in inflammatory bowel disease.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional gastrointestinal disorders (FGIDs) and inflammatory bowel disease (IBD) are common clinical disorders characterized by recurrent diarrhea and abdominal pain. Although their pathogenesis has not been fully clarified, disruptions in intestinal motility and immune function are widely accepted as contributing factors to both conditions, and the brain-gut axis plays a key role in these processes. Traditional Chinese Medicine (TCM) employs a holistic approach to treatment, considers spleen and stomach impairments and liver abnormality the main pathogenesis of these two diseases, and offers a unique therapeutic strategy that targets these interconnected pathways. Clinical evidence shows the great potential of TCM in treating FGIDs and IBD. This study presents a systematic description of the pathological mechanisms of FGIDs and IBD in the context of the brain-gut axis, discusses clinical and preclinical studies on TCM and acupuncture for the treatment of these diseases, and summarizes TCM targets and pathways for the treatment of FGIDs and IBD, integrating ancient wisdom with contemporary biomedical insights. The alleviating effects of TCM on FGID and IBD symptoms are mainly mediated through the modulation of intestinal immunity and inflammation, sensory transmission, neuroendocrine-immune network, and microbiota and their metabolism through brain-gut axis mechanisms. TCM may be a promising treatment option in controlling FGIDs and IBD; however, further high-quality research is required. This review provides a reference for an in-depth exploration of the interventional effects and mechanisms of TCM in FGIDs and IBD, underscoring TCM's potential to recalibrate the dysregulated brain-gut axis in FGIDs and IBD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.